A phase 2 study from Spiera et al. found that patients with glucocorticoid-dependent PMR taking the antibody-drug conjugate ABBV-154 had a longer time to flare compared with those taking placebo, supporting further investigation.
A Joint Doctor with Joint Disease
This year, Dr. Sam Shapiro underwent total hip arthroplasty. Her journey from being an athlete to suffering from arthritis and chronic joint pain was difficult. Here is her story, complete with post-op insights.
JAK Inhibitors 101
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
The Long Silk Road
Matteo Piga, MD, highlighted the latest research into Behçet’s disease, including developments into the understanding of its pathophysiology and positive results for potential treatments.
Finding the Panacea
Janus kinase (JAK) inhibitors, biologics and more—Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.
FDA Approves Ustekinumab-stba for All Forms & Dosages as Its Reference Product
Ustekinumab-stba (Steqeyma) now has FDA approval for all forms and dosages of its reference product, ustekinumab (Stelara), including a subcutaneous injection to treat pediatric patients with plaque psoriasis or psoriatic arthritis.
B Original: B Cells, Non-Invasive Biomarkers & More
Experts discussed how aspects of the immune system other than B cells play a role in lupus, including mitochondria in red blood cells, proteins present in urine and more.
Highlights from the European Congress of Internal Medicine
An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.
New Study: Upadacitinib Is Treatment Option for Giant Cell Arteritis
Results of the international SELECT-GCA study suggest that upadacitinib may be an effective new oral treatment for giant cell arteritis.
Case Report: Giant Cell Arteritis Presenting with Scalp Necrosis
Giant cell arteritis (GCA), is an inflammatory vasculitis that involves large- and mediumsized arteries, most commonly the cranial branches of the carotid artery.1 It is seen in individuals 50 years and older.1 The most typical manifestation is new-onset headache with scalp tenderness and jaw claudication. 2 The most feared complication associated with GCA is permanent…
- 1
- 2
- 3
- …
- 341
- Next Page »